The most promising drug currently under investigation for obesity targeting the amylin pathway is cagrilintide (formerly AM‐833), developed by Novo Nordisk, demonstrating effectiveness in preclinical studies, particularly when combined with semaglutide.222. This evidence concerns the gene IAPP and Obesity.